Mindray Medical has entered into an agreement to acquire a controlling stake of China-based Suzhou Hyssen Electronics.
Hyssen makes automated urine sediment analyzers in China.
Mindray expects to combine its engineering, manufacturing, sales and management platforms with Hyssen’s technology and expertise in urine sediment analysis.
Urine sediment analysis can detect kidney and urinary tract diseases by analyzing blood cells, bacteria, urinary casts etc in urine samples.
Urine sediment and dry chemistry analysis form urinalysis.
Urinalysis, hematology and biochemistry analysis are the three most common methods used in in-vitro diagnostic market.
Mindray chief strategic officer Minghe Cheng said Hyssen’s products complement their current in-vitro diagnostic product offerings in urine dry chemistry, hematology and biochemistry.
"With the new additions, we believe that our in-vitro diagnostic segment can now provide our customers with better and more complete solutions," Cheng said.